TARSUS PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), Net of Tax
TARSUS PHARMACEUTICALS, INC. (TARS) reported Other Comprehensive Income (Loss), Net of Tax of -$259.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$259.00K.
- TARSUS PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$679.00K.
- TARSUS PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $250.00K, a 52.11% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-06-30 was -$46.00K.
- TARSUS PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2025 was $202.00K, a 11.60% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2024 was $181.00K, a 151.39% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2023 was $72.00K.
- TARSUS PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2022 was -$74.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$259.00K 10-Q · filed 2026-08-06 | -$938.00K derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$679.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $202.00K 10-K · filed 2026-02-23 | |||
| 2025-09-30 | $250.00K 10-Q · filed 2025-11-04 | $204.00K derived: sum of 2 quarters · filed 2026-08-06 | $110.00K derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$46.00K 10-Q · filed 2026-08-06 | -$140.00K derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$94.00K 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $181.00K 10-K · filed 2026-02-23 | |||
| 2024-09-30 | $522.00K 10-Q · filed 2025-11-04 | $409.00K derived: sum of 2 quarters · filed 2025-11-04 | $348.00K derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | -$113.00K 10-Q · filed 2025-11-04 | -$174.00K derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | -$61.00K 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $72.00K 10-K · filed 2026-02-23 | |||
| 2023-09-30 | $15.00K 10-Q · filed 2024-11-13 | $62.00K derived: sum of 2 quarters · filed 2024-11-13 | $66.00K derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $47.00K 10-Q · filed 2024-11-13 | $51.00K derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $4.00K 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | -$74.00K 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |